Stopping GLP-1RA Linked to Increased Depression and Anxiety in Type 2
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Stopping GLP-1RA Linked to Increased Depression and Anxiety in Type 2
A recent large-scale cohort study sheds new light on the psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used drugs for managing type 2 diabetes. While previous research has shown mixed results regarding the psychiatric effects of GLP-1RAs during active treatment, this groundbreaking analysis from the Shanghai Hospital Link Database focuses on the largely unexplored period following discontinuation of t…
GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes
July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association. These findings from an observational analysis study were published by Akiva Rosenzveig, MD, et al in the Journal of the …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
